Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1944 - The impact of Oncotype DX breast cancer assay results on clinical practice – a UK experience


11 Sep 2017


Poster display session


Targeted Therapy;  Breast Cancer


Valerie Crolley


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


V.E. Crolley1, H. Marashi2, S.K.R. Rawther3, M. Parton4, J. Graham5, A. Vinayan6, S. Sutherland7, A. Rigg8, A. Wadhawan9, C. Harper-Wynne10, E. Spurrell11, H. Bond12, F. Raja13, J. King14

Author affiliations

  • 1 Oncology, Royal Free Hospital, NW3 2QG - London/GB
  • 2 Oncology, Beatson West of Scotland Cancer Centre, Glasgow/GB
  • 3 Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/GB
  • 4 Oncology, Royal Marsden NHS Foundation Hospital, London/GB
  • 5 Oncology, South Tees NHS Foundation Trust, Northallerton/GB
  • 6 Oncology, East And North Hertfordshire NHS Trust, Stevenage/GB
  • 7 Oncology, Mount Vernon Cancer Centre, London/GB
  • 8 Oncology, Guys and St Thomas NHS Foundation Trust, London/GB
  • 9 Oncology, Velindre NHS Trust, Cardiff/GB
  • 10 Oncology, Maidstone and Tunbridge Wells NHS Trust, Maidstone/GB
  • 11 Oncology, The Whittington Hospital NHS Trust, London/GB
  • 12 Oncology, Royal Cornwall Hospitals NHS Trust, Truro/GB
  • 13 Oncology, University College London Hospitals NHS Foundation Trust, London/GB
  • 14 Medical Oncology, Royal Free Hospital, London, NW3 2QG - London/GB


Abstract 1944


Gene expression profiling is increasingly being used by clinicians to help determine whether or not to offer adjuvant chemotherapy. Oncotype DX is a 21 gene panel developed to predict the risk of tumour recurrence in patients with oestrogen receptor (ER) positive, HER2 negative breast cancer. NICE has recommended its use for patients at intermediate risk of recurrence, where this information would help clinicians to assess the potential benefit of chemotherapy versus endocrine therapy alone. Our aim was to see how oncologists are interpreting Oncotype DX tests in their clinical practice.


Data on patient and tumour characteristics (size, grade, ER/PR/HER2/nodal status), Oncotype DX recurrence score, treatment options offered and treatment outcomes were collected from 14 cancer centres across the UK.


Of the 628 patients tested, 317 (50%) were in the low risk category (recurrence score


Throughout the UK, about half of patients tested had low risk Oncotype scores and the majority (74.1%) of patients tested did not receive chemotherapy. The widest variation in clinical practice was observed in interpreting intermediate risk Oncotype results, and in the chemotherapy regimens offered.

Clinical trial identification

Legal entity responsible for the study

Judy King




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.